| Primary |
| Mantle Cell Lymphoma |
20.2% |
| Prophylaxis |
15.6% |
| Bone Marrow Transplant |
11.0% |
| Chronic Graft Versus Host Disease |
8.3% |
| Non-hodgkin's Lymphoma |
7.3% |
| Chemotherapy |
6.4% |
| Ewing's Sarcoma |
5.5% |
| Prophylaxis Against Graft Versus Host Disease |
5.5% |
| Convulsion Prophylaxis |
3.7% |
| Product Used For Unknown Indication |
3.7% |
| Acute Graft Versus Host Disease |
2.8% |
| Neuroblastoma |
2.8% |
| Allogenic Bone Marrow Transplantation Therapy |
1.8% |
| Hypertension |
1.8% |
| Myelodysplastic Syndrome |
1.8% |
| Graft Versus Host Disease |
0.9% |
| Prophylaxis Against Transplant Rejection |
0.9% |
|
| Venoocclusive Disease |
23.3% |
| Thrombocytopenia |
10.0% |
| Weight Increased |
10.0% |
| Dermatitis Bullous |
6.7% |
| Mucosal Inflammation |
6.7% |
| Primary Adrenal Insufficiency |
6.7% |
| Rheumatoid Factor Positive |
6.7% |
| Chronic Obstructive Pulmonary Disease |
3.3% |
| Epistaxis |
3.3% |
| Interstitial Lung Disease |
3.3% |
| Leukaemia Recurrent |
3.3% |
| Multi-organ Failure |
3.3% |
| Nervous System Disorder |
3.3% |
| Neutropenic Sepsis |
3.3% |
| Pulmonary Alveolar Haemorrhage |
3.3% |
| Septic Shock |
3.3% |
|
| Secondary |
| Stem Cell Transplant |
19.6% |
| Bone Marrow Conditioning Regimen |
17.9% |
| Product Used For Unknown Indication |
13.1% |
| Prophylaxis Against Graft Versus Host Disease |
12.6% |
| Bone Marrow Transplant |
6.7% |
| Acute Myeloid Leukaemia |
5.0% |
| Prophylaxis |
4.8% |
| Neuroblastoma |
4.3% |
| Antifungal Prophylaxis |
3.1% |
| Prophylaxis Against Transplant Rejection |
2.4% |
| Graft Versus Host Disease |
1.9% |
| Lung Neoplasm |
1.9% |
| Cardiac Failure |
1.4% |
| Allogenic Bone Marrow Transplantation Therapy |
1.0% |
| Immunosuppression |
1.0% |
| T-cell Depletion |
1.0% |
| Autologous Peripheral Hematopoietic Stem Cell Transplant |
0.7% |
| Immunosuppressant Drug Therapy |
0.7% |
| Antiviral Prophylaxis |
0.5% |
| Chronic Myeloid Leukaemia |
0.5% |
|
| Sarcoidosis |
10.2% |
| Venoocclusive Disease |
10.2% |
| Acute Graft Versus Host Disease |
6.8% |
| Graft Versus Host Disease |
6.8% |
| Thrombocytopenia |
6.8% |
| Thrombotic Microangiopathy |
6.8% |
| Post Transplant Lymphoproliferative Disorder |
5.1% |
| Sepsis |
5.1% |
| Skin Lesion |
5.1% |
| Venoocclusive Liver Disease |
5.1% |
| Chronic Graft Versus Host Disease |
3.4% |
| Cytomegalovirus Infection |
3.4% |
| Hypothyroidism |
3.4% |
| Interstitial Lung Disease |
3.4% |
| Osteonecrosis |
3.4% |
| Pneumonia |
3.4% |
| Renal Failure |
3.4% |
| Somnolence |
3.4% |
| Toxic Encephalopathy |
3.4% |
| Acute Graft Versus Host Disease In Skin |
1.7% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
20.5% |
| Graft Versus Host Disease |
14.7% |
| Stem Cell Transplant |
11.1% |
| Bone Marrow Transplant |
8.9% |
| Bone Marrow Conditioning Regimen |
7.3% |
| Product Used For Unknown Indication |
6.6% |
| Therapeutic Procedure |
5.3% |
| Premedication |
5.1% |
| Unrelated Donor Bone Marrow Transplantation Therapy |
4.1% |
| Prophylaxis |
2.8% |
| Chemotherapy |
2.3% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Antibiotic Prophylaxis |
1.8% |
| Antifungal Prophylaxis |
1.5% |
| Myelodysplastic Syndrome |
1.3% |
| Neuroblastoma |
1.3% |
| Cord Blood Transplant Therapy |
1.0% |
| Prophylaxis Against Transplant Rejection |
1.0% |
| Adrenogenital Syndrome |
0.8% |
| Infantile Genetic Agranulocytosis |
0.8% |
|
| Sepsis |
24.1% |
| Venoocclusive Disease |
11.1% |
| Staphylococcal Infection |
7.4% |
| Weight Increased |
7.4% |
| Infection |
5.6% |
| Graft Versus Host Disease |
3.7% |
| Lichenification |
3.7% |
| Nephrotic Syndrome |
3.7% |
| Respiratory Syncytial Virus Infection |
3.7% |
| Thrombotic Microangiopathy |
3.7% |
| Treatment Noncompliance |
3.7% |
| Viral Haemorrhagic Cystitis |
3.7% |
| Vitiligo |
3.7% |
| Vomiting |
3.7% |
| Acute Graft Versus Host Disease In Liver |
1.9% |
| Drug Ineffective For Unapproved Indication |
1.9% |
| Dyspnoea |
1.9% |
| Herpes Simplex |
1.9% |
| Hypertension |
1.9% |
| Hyponatraemia |
1.9% |
|
